Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:2/17/2010

s they enter Phase III.  A major drug for a large unmet medical need, unencumbered by a partnership in the biggest markets!

We feel that we have created a great situation and opportunity for our shareholders with the development of Multikine as a first-line treatment for cancer.  We have a great team and, for the first time, the funds to execute our plans.

We have also advanced with the very rapid development of our investigational treatment for H1N1 hospitalized patients.  This treatment is based on our LEAPS technology which allows us to direct an immune response outcome.  During the height of the H1N1 wave in the fall of 2009 we worked as fast as possible to move into clinical trials for this new investigational treatment of hospitalized H1N1 patients, as these patients are at serious risk of dying.  We started a study at the Johns Hopkins University School of Medicine in November 2009.  This study needs to enroll 20 H1N1 hospitalized patients and 20 healthy individuals as the control group.  We are waiting for Johns Hopkins to complete the study.  Patient enrollment is completely dependent on patient availability of H1N1 hospitalized patients at Johns Hopkins.

Currently H1N1 does not appear to be a big problem in the US.  However, it continues to infect and kill patients in other places around the world.  Some people think that H1N1 is gone, like Avian Flu and SARS appear to be gone.  H1N1 is different though.  H1N1 has already infected different populations all over the world.  It is the first flu virus that can infect humans throughout all four seasons.  As a flu virus it undergoes rapid mutations.  As such, similar to the normal seasonal flu, we are likely to see H1N1 reappear in a mutated form.  Our greatest fear is that it migh
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Pa. , Sept. 1, 2015 ... fully integrated specialty pharmaceutical company focused on discovering, ... that researchers will be  presenting scientific data on ... an abuse-deterrent, extended-release, oral morphine product candidate, and ... development, at PainWeek 2015 to be ...
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, ... of the cardiovascular image management market, Frost ... with the 2015 European Frost & Sullivan ... Netherlands -based PMI has designed innovative ... product lines—which deliver precise and reproducible quantitative ...
(Date:9/1/2015)... , September 1, 2015 BerGenBio ... today announces that it has appointed Hilde Furberg ... Directors to its Board of Directors, effective immediately. ... of experience in pharma and biotech and is currently ... Sanofi company. Previously her role was Vice President and ...
Breaking Medicine Technology:Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 2Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 3Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 4Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 5BerGenBio Appoints Non-Executive Directors 2
... Oct. 25 The National Community Pharmacists Association (NCPA) ... Digest, sponsored by Cardinal Health , which found that ... their business in 2009 despite a stagnant economy, the ... drug reimbursements and the questionable business practices of pharmacy ...
... Panasonic Corporation of North America has completed an investment ... Medical Technologies which works closely with the Texas Medical ... establish itself as a global leader in Personalized Preventive ... to establish a presence in the world,s largest medical ...
Cached Medicine Technology:NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 2NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 3NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 4Panasonic Makes Investment in Houston-based CardioNexus Corp. 2Panasonic Makes Investment in Houston-based CardioNexus Corp. 3Panasonic Makes Investment in Houston-based CardioNexus Corp. 4
(Date:9/1/2015)... New York, NY (PRWEB) , ... September 01, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – today announced its annual Light it Red for Lymphoma awareness ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted ... ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn ... some of whom work for Calvary, and two junior counselors who were campers themselves ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia ... and universities across the country in stemming sexual assaults on their campuses. , ... (ARC3), a consortium of sexual assault researchers and student affairs professionals responding to ...
(Date:9/1/2015)... Minnesota (PRWEB) , ... September 01, 2015 , ... ... health care delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) ... in 2016. , Based in San Francisco, Doctor On Demand provides immediate ...
(Date:9/1/2015)... ... 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and ... her firm’s success in the hair care and distribution industry through her combination ... will be providing “Look and learn” live demonstrations, as well as promoting her ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
... companies to different moral standards than other organizations, according ... Consumer Research . "Imagine the CEO of ... the business of maximizing shareholder profitability and fully intends ... prices should be very high because of limited competition," ...
... bed has to deal with numerous complications. Frequently, they ... them. Bony prominences, such as the sacrum, coccyx and ... to tissue necrosis. Damage can extend into the periosteum ... are entryways for germs, which can trigger sepsis. While ...
... the US Prostate Cancer Prevention Trial found cancer in many ... debated which PSA level should lead to a biopsy recommendation. ... amid considerable controversy, that the evidence does not support recommending ... because the risks outweigh the benefits. Now, a study ...
... MONDAY, Dec. 12 (HealthDay News) -- Acupuncture may help ... to a new study. Cancer drugs called taxanes, ... especially in the calves and feet, resulting in severe ... no effective treatment for the condition, called chemotherapy induced ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... drugs for attention deficit-hyperactivity disorder (ADHD) do not seem to ... finds. There have been fears that these drugs can ... large, observational study found no evidence that these effects posed ...
... -- A 59-year-old woman from upstate New York and ... were the first patients in New York state and ... transplanted lungs that were assessed and reconditioned in the ... to dramatically increase the availability of lungs for transplant. ...
Cached Medicine News:Health News:Commercial or communal: Why is outsourcing taboo for churches and pharmaceutical companies? 2Health News:Lying and sitting more comfortably 2Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:Acupuncture Might Ease Chemotherapy Pain 2Health News:ADHD Drugs Don't Raise Risk of Heart Problems: Study 2Health News:ADHD Drugs Don't Raise Risk of Heart Problems: Study 3Health News:NewYork-Presbyterian/Columbia surgeons perform first 'ex vivo' lung transplants in New York 2
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Rigid Endoscopes....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: